Recent Research Analysts’ Ratings Updates for AbbVie (ABBV)

Several brokerages have updated their recommendations and price targets on shares of AbbVie (NYSE: ABBV) in the last few weeks:

• 12/13/2025 – AbbVie was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – AbbVie had its price target raised by analysts at Morgan Stanley from $261.00 to $269.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – AbbVie was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $265.00 price target on the stock, up previously from $225.00.
• 12/10/2025 – AbbVie was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating.
• 11/30/2025 – AbbVie was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/22/2025 – AbbVie was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/13/2025 – AbbVie is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $280.00 price target on the stock.
• 11/12/2025 – AbbVie was upgraded by analysts at Scotiabank to a “strong-buy” rating.
• 11/7/2025 – AbbVie had its price target raised by analysts at UBS Group AG from $195.00 to $220.00. They now have a “neutral” rating on the stock.
• 11/5/2025 – AbbVie had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $289.00 price target on the stock, up previously from $284.00.
• 11/4/2025 – AbbVie was downgraded by analysts at DZ Bank AG from a “buy” rating to a “hold” rating. They now have a $237.00 price target on the stock.
• 11/3/2025 – AbbVie had its price target lowered by analysts at Citigroup Inc. from $240.00 to $235.00. They now have a “neutral” rating on the stock.
• 11/3/2025 – AbbVie was given a new $256.00 price target on by analysts at Raymond James Financial, Inc..
• 11/3/2025 – AbbVie had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an “overweight” rating on the stock.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio is currently 496.97%.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.